Gastroenterology
Premature death was defined as death before age 75 years, which was the primary study outcome.
The U.S. FDA approved Tremfya for the treatment of adults with moderately to severely active Crohn disease.
At baseline and after 2 months, patients underwent clinical assessments, WHOQOL-BREF evaluation, and 24-hour dietary recalls.
People with CD who have associated joint inflammation due to immune system dysfunction carry distinct gut bacteria.
The primary study outcome was the development of endoscopic inflammatory pouch disease.
An increase in intestinal permeability allows gut bacteria to reach bone marrow.
Advertisement
Expert Interviews on Gastroenterology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.